ADVANCING MOST-FAVORED-NATION (MFN) PRICING:
In a bold move that could reshape the landscape of prescription drug pricing in America, President Donald J. Trump has announced new agreements with pharmaceutical giants Eli Lilly and Company and Novo Nordisk. These agreements promise to significantly reduce the costs Americans face for some of the most commonly prescribed medications.
- This groundbreaking agreement aims to slash prices on two of the most expensive drugs used by Americans, particularly for adults dealing with diabetes, heart disease (applicable for Ozempic and Wegovy), obesity, and other health conditions.
- Under this plan, the monthly costs for Ozempic and Wegovy will plummet from $1,000 and $1,350, respectively, to just $350 when purchased through TrumpRx.
- If approved, the monthly price for Zepbound and Orforglipron will also see a significant cut, dropping from $1,086 to an average of $346 via TrumpRx.
- Should the FDA greenlight the Wegovy pill or similar “GLP-1” drugs currently in development, the introductory monthly cost will be set at $150 through TrumpRx.
- This historic price reduction, brokered by President Trump, will allow Medicare and Medicaid to provide obesity medications to adults at a fraction of the cost proposed under the Biden Administration.
- Medicare will offer Ozempic, Wegovy, Mounjaro, and Zepbound at $245 monthly—less than half of the previous proposals. State Medicaid programs will also benefit from these reduced prices.
- For the first time, Medicare can cover Wegovy and Zepbound for patients with obesity and related health issues due to these lower costs.
- Beneficiaries of Medicare will see their co-pay reduced to a mere $50 per month.
- The agreements also usher in lower prices for additional Eli Lilly and Novo Nordisk products when acquired through TrumpRx. For instance:
- Eli Lilly will offer Emgality, a migraine treatment, at $299 per pen, a remarkable discount of $443 from the original list price.
- Trulicity, a widely used diabetes medication, will be available for $389 per month, representing a $598 reduction from the standard price.
- Moreover, Novo Nordisk will provide essential insulin products, such as NovoLog and Tresiba, at just $35 per month.
- Furthermore, the agreement stipulates that Eli Lilly and Novo Nordisk must guarantee MFN prices on all forthcoming medicines they introduce to the market, ensuring that increased foreign revenue from existing products will be repatriated. Every State Medicaid program will have access to these MFN drug prices as well.
INVESTING IN AMERICA TO SECURE PHARMACEUTICAL SUPPLY CHAINS:
In a display of commitment to bolstering domestic production, Eli Lilly and Novo Nordisk are announcing significant investments aimed at enhancing U.S. manufacturing capabilities.
- Novo Nordisk has pledged an additional $10 billion to strengthen its domestic operations, particularly for the potential U.S. production of the Wegovy tablet, contingent on FDA approval.
- Under President Trump’s stewardship, Eli Lilly has committed to at least $27 billion in new investments focused on U.S. manufacturing.
MAKING AMERICA HEALTHY AGAIN:
President Trump has reiterated his commitment to revamping the American healthcare system to prioritize health and address the underlying causes of chronic diseases. Today’s announcements mark a substantial step toward fulfilling this promise.
- The Centers for Disease Control and Prevention (CDC) estimate that a staggering 40% of American adults are classified as obese.
- This obesity epidemic is a significant contributor to chronic diseases, heightening the risks of type 2 diabetes, hypertension, heart issues, strokes, and certain cancers, among others.
- The current announcement opens the door to potentially life-altering medications for adults grappling with obesity, offering a unique chance to tackle the obesity epidemic and its associated chronic health crises, especially when paired with lifestyle modifications aimed at long-term health improvement.
- The Administration remains steadfast in its holistic “Make America Healthy Again” strategy, which seeks to realign incentives, encourage private-sector collaboration, enhance public awareness regarding diet and exercise, and promote vital research.
ENDING GLOBAL FREELOADING ON AMERICAN PHARMACEUTICAL INNOVATION:
President Trump is taking significant steps to rectify a system that has allowed pharmaceutical companies to charge American consumers exorbitantly while offering lower prices to wealthier nations.
- Recent statistics reveal that Americans pay more than three times for brand-name drugs compared to their counterparts in other developed countries, even after factoring in the discounts provided by manufacturers.
- Despite comprising less than 5% of the global population, the United States accounts for approximately 75% of global pharmaceutical profits, a situation that places undue financial burden on American taxpayers.
- Pharmaceutical companies benefit from generous research grants and substantial healthcare spending from the U.S. Government. Rather than passing these savings onto American consumers, many companies opt to offer discounted prices abroad, effectively subsidizing foreign markets at the expense of American consumers.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST:
President Trump is fulfilling commitments to prioritize American patients, countering skepticism from the political establishment regarding the feasibility of these reforms.
- On May 12, 2025, President Trump signed an Executive Order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” directing the Administration to implement various measures to align American drug prices with those in similar nations.
- On July 31, 2025, he communicated with major pharmaceutical manufacturers, outlining the necessary steps to lower prescription drug prices in the U.S. to match the lowest offered prices in other developed countries.
- Since September 30, 2025, President Trump has announced five agreements with leading pharmaceutical manufacturers aimed at aligning prices with those paid in other developed nations, promising considerable relief for millions of Americans.
- President Trump has been relentless in his pursuit of reducing the unfair and exorbitant prices that Americans face for prescription drugs:
- President Trump stated, “In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home. So we would spend tremendous amounts of money to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything—four times, five times different.”
